Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.00
Bid: 41.00
Ask: 43.00
Change: 1.50 (3.70%)
Spread: 2.00 (4.878%)
Open: 41.50
High: 42.00
Low: 41.50
Prev. Close: 40.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Bosch UK to work with Pulsiv Solar

8 Apr 2019 07:00

RNS Number : 3588V
Frontier IP Group plc
08 April 2019
 

8 April 2019

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Bosch UK to work with Pulsiv Solar to optimise energy efficient solar power technology

 

 

Frontier IP, a specialist in commercialising university intellectual property, today announces that Robert Bosch Limited ("Bosch UK") has entered into an agreement to work with portfolio company Pulsiv Solar ("Pulsiv" or the "Company") to optimise the design of the Company's energy-efficient solar micro-inverter prototype. Frontier IP holds an 18.9 per cent stake in Pulsiv.

 

When the prototype moves into full-scale production University of Plymouth spin-out Pulsiv will be able to market the devices as "Engineered by Bosch." Bosch UK is a subsidiary of Robert Bosch GmbH ("Bosch"), a leading global supplier of technology and services that employs roughly 410,000 associates worldwide.

 

Solar micro-inverters are plug-in devices that convert direct current (DC) electricity generated by photovoltaic cells to alternating current (AC) used in electrical grids. In laboratory conditions, Pulsiv has demonstrated its technology is significantly more energy efficient than existing micro-inverters.

 

For the commercial product, the Company is targeting an improvement on energy delivered to the grid of at least 5 per cent over current market leaders. Its micro-inverters can be used in new installations or retrofitted to existing solar panels.

 

The work with Bosch UK will be funded by the Company as part of a £288,732 project backed by a £129,929 grant from Innovate UK, the UK's innovation agency.

 

Other applications being explored for the technology include improving the energy efficiency of power converters used in a huge range of consumer devices, such as televisions, mobile phones and laptops.

 

Pulsiv was incorporated to develop and commercialise the work of Dr Zaki Ahmed, Associate Professor in Information Technology at the School of Computing, Electronics and Mathematics at the University.

 

Mahesh Chikodi, UK country head of Robert Bosch Engineering and Business Solutions, said:

"Bosch is currently engaged with Pulsiv Solar for industrialisation of their solution which increases the power output from solar panels. Pulsiv has technology which increases the output of solar panels by up to 30 per cent and Bosch with its leading engineering expertise on software and sensors will aim to accelerate the product development and testing."

 

Pulsiv Solar technical director Dr Zaki Ahmed said: "We are very excited to have Bosch's collaboration and support on the industrialisation of our micro-inverter, and potentially other products. This collaboration means I expect Pulsiv will be able to deliver an average improvement of more than 5 per cent in the energy exported to the electrical grid. We have been assured by a global leader in the renewables space that this improvement could be disruptive to the industry."

 

Frontier IP chief executive officer Neil Crabb said: "We are very pleased with the progress Pulsiv Solar is making. This agreement with Bosch supports validation of the Company's patented photovoltaic inverter technology and we are looking forward to developments across other applications in the future."

 

 

ENQUIRIES

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser and Broker)

T: 0203 328 5656

Nick Athanas / Nicholas Chambers (Corporate Finance)

Amrit Nahal (Equity Sales)

 

ABout frontier IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

Frontier IP is the commercialisation partner for the University of Plymouth.

ABOUT THE UNIVERSITY OF PLYMOUTH

 

The University of Plymouth is renowned for high quality, internationally-leading education, research and innovation.

 

With a mission to Advance Knowledge and Transform Lives, Plymouth is a *top 50 research university with clusters of world class research across a wide range of disciplines including marine science and engineering, medicine, robotics and psychology. A twice winner of the Queen's Anniversary Prize for Higher Education, the University of Plymouth continues to grow in stature and reputation.

 

It has a strong track record for teaching and learning excellence and has one of the highest numbers of National Teaching Fellows of any UK university. With 21,000 students, and a further 17,000 studying for a Plymouth degree at partner institutions in the UK and around the world, and over 100,000 alumni pursuing their chosen careers globally, it has a growing global presence.

http://www.plymouth.ac.uk

* Research Fortnight Research Power League Table 2014.

About Bosch:

The Bosch Group is a leading global supplier of technology and services. It employs roughly 410,000 associates worldwide. According to preliminary figures, the company generated sales from operations of 77.9 billion euros in 2018. Its operations are divided into four business sectors: Mobility Solutions, Industrial Technology, Consumer Goods, and Energy and Building Technology. As a leading IoT company, Bosch offers innovative solutions for smart homes, smart cities, connected mobility, and connected manufacturing. It uses its expertise in sensor technology, software, and services, as well as its own IoT cloud, to offer its customers connected, cross-domain solutions from a single source.

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAUBUVRKUASRAR
Date   Source Headline
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.